Sunib 12.5mg (Sunitinib Malate) is a targeted cancer therapy manufactured by Pharma Lord. Sunitinib Malate is a multi-kinase inhibitor that works by blocking multiple enzymes involved in the growth, replication, and spread of cancer cells. This oral medication is used to treat several types of cancer, particularly renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (pNET).
Advantages of Sunitinib Malate:
- Multi-Targeted Action: Sunitinib inhibits multiple receptor tyrosine kinases (RTKs), which are responsible for tumor growth, angiogenesis (new blood vessel formation), and metastasis.
- Effective in Multiple Cancer Types: It is proven effective in treating several difficult-to-treat cancers, such as advanced kidney cancer, GIST, and pNET.
- Oral Treatment: Administered orally, making it convenient for patients as it avoids frequent hospital visits for injections or infusions.
- Slows Tumor Growth: Sunitinib not only inhibits tumor growth but also prevents new blood vessels from supplying the tumor, effectively starving it of the nutrients it needs to grow.
- Prolonged Survival: It has shown the ability to extend survival in patients with metastatic renal cell carcinoma and other advanced cancers.
- Potential for Combination Therapy: Sunitinib is also being explored for use in combination with other therapies to enhance overall treatment efficacy.
Uses of Sunib 12.5mg:
- Renal Cell Carcinoma (RCC): Used for the treatment of advanced kidney cancer (RCC), particularly in cases where surgery is not an option.
- Gastrointestinal Stromal Tumors (GIST): Prescribed for patients with GIST who are resistant to or cannot tolerate imatinib (another cancer therapy).
- Pancreatic Neuroendocrine Tumors (pNET): Effective in treating advanced pNET, especially in patients with inoperable or metastatic disease.
- Other Tumor Types: Investigated for its potential in treating other tumors driven by abnormal RTK signaling.